XML 51 R42.htm IDEA: XBRL DOCUMENT v3.22.4

Earnings per share (Tables)

6 Months Ended

Dec. 31, 2022

Text block [abstract]

Summary of earnings per share

		Consolidated December 2022				Consolidated December 2021 Restated*
		$				$
Loss after income tax attributable to the owners of Kazia Therapeutics Limited			(13,586,027	)			(13,201,848	)
		Number				Number
Weighted average number of ordinary shares used in calculating basic earnings per share			145,661,097				132,014,383
Weighted average number of ordinary shares used in calculating diluted earnings per share			145,661,097				132,014,383
		Cents				Cents
Basic earnings per share			(9.327	)			(10.000	)
Diluted earnings per share			(9.327	)			(10.000	)

X

- Definition

The disclosure of earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 33
-IssueDate 2022-03-24
-Paragraph 66
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_EarningsPerShareExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Text block [abstract]

+ References

No definition available.

+ Details

Name:	kzia_TextBlockAbstract
Namespace Prefix:	kzia_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration